Cancer is the leading cause of premature death in France, with more than 157,000 deaths in 2018 and 382,000 new cases diagnosed. Five-year survival rates vary significantly depending on the type of cancer: 88% for breast cancer, but only 16% for lung cancer. The majority of cancer deaths occur in patients with metastases, classified as Stage IV without specific distinctions based on the affected organs or the degree of invasion, although these factors have a significant impact on prognosis.
The NEMO-PET project (ANR JCJC) aims to identify and characterize different metastatic profiles through an in-depth analysis of 18F-FDG PET/CT images. The main hypothesis is that the precise localization of tumor lesions, tissue invasion, and the distribution of metabolic activity across multiple organs influence the progression of the disease. By combining this information with clinical and biological data (including molecular profiles), it may be possible to identify groups of metastatic patients with different prognoses, thereby optimizing their care.